Table 4.
ELISA confirmation using serum samples from each patient in the good prognosis group
| Patient | Good prognosis (ITIH4) |
|||
|---|---|---|---|---|
| Aa) (ng/mL) | Bb) (ng/mL) | B-A (ng/mL) | Fold change | |
| P1 | 47.9 | 253.3 | 205.4 | 5.3 |
| P2 | 84.6 | 82.5 | ‒2.1 | 1 |
| P3 | 12.8 | 244 | 231.1 | 19 |
| P4 | 34 | 201.1 | 167.1 | 5.9 |
| P5 | 51.9 | 182.1 | 130.2 | 3.5 |
| P6 | 53.1 | 214.6 | 161.5 | 4 |
| P7 | 56.4 | 206.4 | 150 | 3.7 |
| P8 | 13.4 | 176.1 | 162.7 | 13.1 |
| P9 | 35.2 | 40.3 | 5.2 | 1.1 |
| P10 | 36.8 | 217.4 | 180.6 | 5.9 |
| Average | 42.6 | 181.8 | 139.2 | 6.3 |
ELISA, enzyme-linked immunosorbent assay; ITIH4, inter-alpha inhibitor 4; P, patient.
a)
Pre-radiotherapy,
b)
Post-radiotherapy.